Cited by 250Cholesterol and Lipid MetabolismAtherosclerosis and Cardiovascular DiseasesDrug Transport and Resistance Mechanisms

Increased ABCA1 activity protects against atherosclerosis

Open access
Singaraja, Roshni R., Fievet, Catherine, Castro, Graciela, James, Erick R., Hennuyer, Nathalie, Clee, Susanne M., Bissada, Nagat, Choy, Jonathan C. +4 more·2002·Journal of Clinical Investigation

Abstract

The ABC transporter ABCA1 plays a key role in the first steps of the reverse cholesterol transport pathway by mediating lipid efflux from macrophages. Previously, it was demonstrated that human ABCA1 overexpression in vivo in transgenic mice results in a mild elevation of plasma HDL levels and increased efflux of cholesterol from macrophages. In this study, we determined the effect of overexpression of ABCA1 on atherosclerosis development. Human ABCA1 transgenic mice (BAC(+)) were crossed with ApoE(-/-) mice, a strain that spontaneously develop atherosclerotic lesions. BAC(+)ApoE(-/-) mice developed dramatically smaller, less-complex lesions as compared with their ApoE(-/-) counterparts. In addition, there was increased efflux of cholesterol from macrophages isolated from the BAC(+)ApoE(-/-) mice. Although the increase in plasma HDL cholesterol levels was small, HDL particles from BAC(+)ApoE(-/-) mice were significantly better acceptors of cholesterol. Lipid analysis of HDL particles from BAC(+)ApoE(-/-) mice revealed an increase in phospholipid levels, which was correlated significantly with their ability to enhance cholesterol efflux.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1172/jci15748

Cites

45 of 45 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Cholesterol efflux from cells to apolipoprotein A-I (apoA-I) acceptors via the ATP-binding cassette transporters ABCA1 and ABCG1 is central in the antiatherogenic mechanism.

    “Cholesterol efflux from cells to apolipoprotein A-I (apoA-I) acceptors via the ATP-binding cassette transporters ABCA1 and ABCG1 is thought to be central in the antiatherogenic mechanism.”

    From MicroRNA‐33 Deficiency Reduces the Progression of Atherosclerotic Plaque in ApoE <sup>−/−</sup> Mice (2012) · cites this paper as [12]

    The Introduction (p. 1) says ABCA1 plays a key role in cholesterol efflux to ApoA-I and links that process to protection against atherosclerosis. Our copy does not address ABCG1, so it does not support attributing the proposed mechanism to both transporters. (LLM, conf=0.90)

    Experimental — accuracy not yet measured
  • Studies in mice with Abca1 deletion or overexpression generally support that ABCA1 prevents atherosclerosis by maintaining circulating HDL-C levels and cellular cholesterol efflux.

    “Studies in mice in which the Abca1 locus is either deleted or overexpressed generally have supported the hypothesis that ABCA1 significantly prevents atherosclerosis by maintaining circulating HDL-C levels and cellular cholesterol efflux.10–13”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Singaraja, R. R., Fievet, C., Castro, G., James, E. R., Hennuyer, N., Clee, S. M., Bissada, N., Choy, J. C., Fruchart, J.-C., McManus, B. M., Staels, B., & Hayden, M. R.
Affiliations
  • University of British Columbia (CA)
  • Inserm (FR)
Corresponding author
Hayden, Michael R.
Venue
Journal of Clinical Investigation
Published
2002-07-01
Volume
110
Issue
1
Pages
35-42
ISSN
0021-9738 (ISSN-L)
OpenAlex
W2097061706
Cited by
250
References
45
Citations by year
2024: 2 · 2023: 1 · 2022: 5 · 2021: 8 · 2020: 5 · 2019: 3 · 2018: 3 · 2017: 6 · 2016: 11 · 2015: 9 · 2014: 9 · 2013: 10 · 2012: 8
FWCI
22.28
Type
journal article
Language
en
Open access
Locations
  • Journal of Clinical Investigation (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
Canadian Institutes of Health Research
Topics
  • Health Sciences › Medicine › Surgery › Cholesterol and Lipid Metabolism
  • Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases
  • Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
Keywords
ABCA1, atherosclerosis, reverse cholesterol transport, HDL cholesterol, macrophage cholesterol efflux, ApoE-deficient mice, transgenic mice, phospholipids, HDL particle composition, atherosclerotic plaque
MeSH terms
Animals, Apolipoproteins A, Apolipoproteins E, Arteriosclerosis, Biological Transport, Active, Cholesterol, Humans, Lipoproteins, HDL, Macrophages, Mice, Transgenic, Phospholipids, Tissue Distribution, Apolipoprotein A-I, Mice, Knockout, ATP-Binding Cassette Transporters, Mice, ATP Binding Cassette Transporter 1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review